New regulations bring new risks to life sciences firms

The pharmaceutical and life sciences industry is among the most heavily regulated in the world. Today, these companies face unprecedented compliance challenges, and the close regulatory scrutiny to which they are subject is unlikely to abate anytime soon.

State of Compliance 2014: Pharmaceutical and Life Sciences industry brief
 
The impact of Social Media:
The need for speed and agility
 
Implementing an aggregate spend program in a global marketplace
Learn more.
1 2 3

Compliance as a market differentiator for pharma companies

At no time have risk resilience and the need to effectively manage compliance been more important to the pharmaceutical and life sciences industry. Companies have to consider a wide range of emerging risks as they adapt their business to changing regulatory and market-driven pressures, including globalization, the advancement of technology, and the changing expectations of stakeholders. New information systems, strategies and processes to manage compliance are rapidly evolving in response to these pressures. Read more about our service capabilities and risk consulting offerings.

 

State of Compliance 2014: Measuring Compliance Impact

We discuss discuss how measuring the business impact of compliance is often more effective than measuring activity in our State of Compliance 2014 Survey.

 

Performance Governance, Risk and Compliance

PwC's Performance GRC US Leader, Brian Schwartz, discusses why companies must focus on aligning Governance Risk and Compliance activities with business performance drivers.

Contacts